Global Therapeutic Landscape of Leber Congenital Amaurosis Pipeline Review, H2 2017
Overview
Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2319058-leber-congenital-amaurosis-lca-pipeline-review-h2-2017
Top Companies mentioned
AmpliPhi Biosciences Corp
Editas Medicine Inc
Novelion Therapeutics Inc
ProQR Therapeutics NV
Spark Therapeutics Inc
Leber Congenital Amaurosis Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Leber Congenital Amaurosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Leber Congenital Amaurosis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Leber Congenital Amaurosis - Competitive Analysis
Key players are making innovative developments in Leber Congenital Amaurosis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Leber Congenital Amaurosis.
The pipeline guide reviews pipeline therapeutics for Leber Congenital Amaurosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Leber Congenital Amaurosis therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Leber Congenital Amaurosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Leber Congenital Amaurosis.
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2319058-leber-congenital-amaurosis-lca-pipeline-review-h2-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by
Vivian Dsena
on Thursday February 22 2018, 2:50 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
